Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4D | Q08499 | 7/20 | 0.52 |
| ▸ | JAK2 | O60674 | 1/20 | 0.50 |
| ▸ | ADORA2A | P29274 | 4/20 | 0.46 |
| ▸ | LMNA | P02545 | 3/20 | 0.45 |
| ▸ | BRAF | P15056 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.44 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6871008 | 0.87 | JAK2 (0.51) | PDE4DJAK2LMNAMAPTKDM4E | |
| SCHEMBL7145859 | 0.85 | JAK2 (0.54) | PDE4DJAK2LMNAMAPTKDM4E | |
| SCHEMBL7142931 | 0.85 | PDE4D (0.51) | PDE4DLMNABRAFMAPTKDM4E | |
| SCHEMBL7039193 | 0.85 | LMNA (0.61) | PDE4DJAK2LMNAMAPTKDM4E | |
| SCHEMBL7146900 | 0.80 | PDE4D (0.50) | PDE4DJAK2LMNAMAPTKDM4E | |
| SCHEMBL7149099 | 0.80 | KDM4E (0.55) | PDE4DJAK2LMNAMAPTKDM4E | |
| SCHEMBL6870164 | 0.79 | KDM4E (0.58) | PDE4DJAK2LMNAMAPTKDM4E | |
| SCHEMBL7146843 | 0.79 | LMNA (0.49) | PDE4DJAK2LMNAMAPTKDM4E | |
| SCHEMBL7148767 | 0.79 | KDM4E (0.54) | PDE4DLMNAMAPTKDM4E | |
| SCHEMBL7145623 | 0.78 | LMNA (0.48) | PDE4DJAK2ADORA2ALMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6514989-B1 | Has a good affinity to the adenosine receptor and can therefore be used for the treatment or protection of diseases mediated by this receptor | HOFFMANN-LA ROCHE INC. | 2003-02-04 | — | — | US | disclosed |
| US-6514989-B1 | Has a good affinity to the adenosine receptor and can therefore be used for the treatment or protection of diseases mediated by this receptor | HOFFMANN-LA ROCHE INC. | 2003-02-04 | — | — | US | disclosed |
| US-6514989-B1 | Has a good affinity to the adenosine receptor and can therefore be used for the treatment or protection of diseases mediated by this receptor | HOFFMANN-LA ROCHE INC. | 2003-02-04 | — | — | US | disclosed |